Search This Blog

Sunday, April 12, 2026

NYC train, bus robberies climb 21% from same period last year

 Robberies are soaring in the city’s transit system, NYPD data show.

There were 128 muggings on trains and buses as of April 5, a 21% surge over the 106 from the same period last year and experts fear it will get worse.

Felony assaults ticked down 6% in the same period, from 171 to 160, but that sum does not include the three horrific attacks on innocent straphangers Saturday by an unhinged, machete-wielding maniac. Assaults are up 60% when compared to pre-Covid 2019.

Some riders complained that there aren’t enough cops in the subway system.Helayne Seidman for the NY Post

Murder in transit also eked up, to three so far this year from none at the same time in 2025.

Misdemeanor assaults spiked by 12% – from 395 to 441 – and petty larceny saw a 4% bump, from 46 to 57.

Last year saw an all-time low for transit robberies and that’s part of the reason the crime is up, an NYPD spokesman said. There were also only two more incidents so far this year than in 2019, he said. 

Samanteer Beckford, of the Bronx, said whatever is being done to protect straphangers isn’t enough.

“The homeless are an issue,” the 32-year-old said. “More needs to be done.”

Under former Mayor Eric Adams, the NYPD deployed 300 additional officers for train patrols in January 2025 to combat crime and improve the perception of safety. The cops specifically targeted overnight shifts with two officers per train.

Crime went down under that initiative, but overtime cuts in February under Mayor Mamdani’s new administration reduced those patrols.

“It’s concerning because summer is coming,” said former NYPD Detective Michael Alcazar, an adjunct professor at John Jay College of Criminal Justice.

“I think that just shows that the police department is really short on uniformed officers,” he said.

“I’m sure the bad guys are realizing that too,” he said. “They can almost predict where police are going to be and they’re timing it.”

Ronald Stokes, 55, said the city needs more undercover officers on the subways.Helayne Seidman for the NY Post
A homeless person on a Times Square subway platform.Helayne Seidman for the NY Post

Last week, Police Commissioner Jessica Tisch boasted of an impressive overall 5.3% drop in citywide crime and a more modest 1.3% drop in subway crime as of March 29.

“It’s really bad because people are pretty much forced to take the subway because of congestion pricing,” a longtime Bronx police officer said. “Now they’re forced to walk around with their heads on a swivel.”

Robberies in the subway are often driven by kids, the NYPD said, adding that 34% of the incidents so far this year were committed by juveniles and 63% have led to arrests.

A rider who identified himself as Steve, 45, said the number of homeless people in the subway has increased.Helayne Seidman for the NY Post
In one recent robbery, eight people attacked three 18-year-old friends on a Bronx train, beat them and stole their electronics.DCPI

The robbery increase was 54% in January and February, compared to the same period in 2025, coinciding with record cold temperatures and snow that pushed more people onto the city’s crammed trains. The incidents trended downward in March, an NYPD spokesman said.

Riders are on edge after recent crimes, including one in which three friends on a Bronx subway car were beaten, kicked and cut with a knife while a gang of eight strangers stole their electronics.

“The safety on the trains is not good right now,” said Ronald Stokes, 55, an assistant superintendent for NYCHA who lives in Harlem and wants more cops.

“They need to ride the trains … to stand outside the station is one thing but to ride the trains would be a big help.”

Claude Butler, a dispatcher for Charter Communications who also lives in Harlem, said he feels like he always has to be on the defensive in the subway “because you never know what can happen.”

The NYPD released pohtos of the suspects in the March 26 Bronx robbery.DCPI
The robbers punched and kicked the victims on a Bronx train, knifing one of them in the head.DCPI

“Just this morning I had to come with my wife because I don’t feel it’s safe for her to ride alone,” the 62-year-old said. “A lot of times, when I’m not with her, guys approach her. Sometimes they brush up against her.”

He also pointed out that the officers in the system are mainly on the platforms.

“When [the police] are here, I just see them in the stations,” he said. “I don’t see them on the trains… they should ride the trains.”

Three teenagers were attacked by masked goons who punched and kicked them, stabbing one of them and hitting another in the face with a scooter.DCPI
Robbers punched and kicked a 37-year-old man as they snatched his headphones on an E subway at the Grand Avenue subway station in Queens around 3 a.m. March 31, police said.DCPI

Mayor Mamdani campaigned in part on cutting the NYPD’s budget, including shuttering the NYPD’s Strategic Response Group, which handles protests and counter-terrorism.

The city needs to flood the subway with cops for the summer, Alcazar said.

“I think robberies are going to increase because there’s going to be more riders and there’s going to be more bad guys, especially in the subway,” Alcazar said. “We need to have an omnipresence.”

https://nypost.com/2026/04/11/us-news/robberies-climb-21-so-far-this-year-over-the-same-span-last-year/

BioNTech, DualityBio:Efficacy in HER2-Expressing, Recurrent Endometrial Cancer

 

  • Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated patients with HER2-expressing, recurrent endometrial cancer, an area of high unmet medical need
  • Data demonstrated clinically meaningful antitumor activity across all HER2 expression levels and a manageable safety profile, with centrallyi HER2-tested patients showing a confirmed objective response rate of 47.9% in all evaluable patients, 49.3% in patients with prior immune checkpoint inhibitor treatment, and a median progression-free survival of 8.1 months
  • Largest trial to date to report results for a HER2-targeted antibody-drug conjugate in this indication supports potential of trastuzumab pamirtecan in real-world patient populations, including patients with lower HER2 expression levels and prior checkpoint inhibitor treatment

Russia ready to supply gas to the EU if it has surplus, TASS reports

 


Kremlin spokesman Dmitry Peskov said on Sunday that Russia is ready to continue supplying gas to the European Union "if there are volumes remaining after supplies to alternative markets," Russian state news agency TASS reported.


However, Europe will find a way to buy gas even if Russia does not supply it, Peskov said.

https://www.marketscreener.com/news/russia-ready-to-supply-gas-to-the-eu-if-it-has-surplus-tass-reports-ce7e50d9df81f52c

Trump shares article saying he could impose naval blockade on Iran if it won’t ‘bend’

 After US-Iran talks in Islamabad ended with no agreement, US President Donald Trump shares on his Truth Social platform an article suggesting he could impose a naval blockade on Iran if it fails to accept US demands.

The article titled “The Trump card the president holds if Iran won’t bend: a naval blockade,” from pro-Trump outlet Just the News, says the blockade would choke the Iranian economy and pressure Iran’s allies China and India, who rely on Iranian oil exports.

The article says such a move by Trump would “reprise his successful blockade strategy” after a previous naval blockade “brought the Venezuelan economy to its knees” ahead of the US capture of Venezuelan leader Nicolas Maduro in January.

https://www.timesofisrael.com/liveblog_entry/trump-shares-article-saying-he-could-impose-naval-blockade-on-iran-if-it-wont-bend/

https://breakingthenews.net/Article/Israel-on-alert-for-possible-return-to-war-with-Iran/66050409

Saturday, April 11, 2026

Are GLP-1 Drugs Linked to Erectile Dysfunction?

 

  • Prior data are mixed regarding a potential association between GLP-1 medications and erectile dysfunction (ED), a common problem in men with diabetes.
  • This real-world study of men with type 2 diabetes identified a possible modest link between GLP-1 agonist use and ED when compared with DPP-4 inhibitors.
  • The researchers called for randomized trials using a standardized ED assessment to further explore any potential association.

GLP-1 receptor agonist use may be associated with a modest increase in erectile dysfunction (ED) risk in men with type 2 diabetes, a target trial emulation suggested.

Using U.S. electronic health record data, the incidence of an ED diagnosis over nearly 3 years of follow-up was 26% higher among new users of GLP-1 medications versus DPP-4 inhibitor initiators (35.2 vs 28 per 1,000 person-years; HR 1.26, 95% CI 1.08-1.46, P=0.004), reported Yong Chen, PhD, of the University of Pennsylvania in Philadelphia, and colleagues.

The association was generally consistent across demographic and clinical subgroups, but lost significance in a sensitivity analysis that aimed to capture unmeasured confounding or systematic biases (HR 1.23, 95% CI 0.86-1.75), according to the study in eClinicalMedicine.

Furthermore, the results contrast with earlier data and should be considered hypothesis-generating as they "may reflect residual or selection bias," wrote Chen and colleagues. "Future randomized controlled trials with standardized assessment of erectile function and comprehensive longitudinal measurement of treatment exposure are needed to confirm these findings and elucidate the underlying mechanisms."

ED affects nearly 50% of men with type 2 diabetes at some point in their lifetime. The pathophysiology is multifactorial, the researchers explained, "primarily attributed to endothelial dysfunction, impaired nitric oxide signaling, and autonomic neuropathy, which collectively contribute to vascular and neurogenic deficits."

The relationship between use of GLP-1 agonists and ED is "complex," they noted, with some preclinical and clinical data suggesting possible erectile health benefits.

For example, an exploratory analysis of the randomized REWIND trial found that slightly fewer men developed erectile dysfunction in the group assigned to dulaglutide (Trulicity) than in the placebo group over more than 5 years of median follow-up (HR 0.92, 95% CI 0.85-0.99, P=0.021).

Meanwhile, a cohort study using the TriNetX database reported higher ED risk and increased use of PDE5 inhibitors such as sildenafil (Viagra) among nondiabetic men with obesity prescribed semaglutide (Ozempic, Wegovy), compared with nonusers.

"These conflicting findings between real-world evidence and trial-based data underscore the need for further mechanistic and prospective studies to clarify the net effect of GLP-1 receptor agonists on sexual health," Chen and colleagues noted.

Their target trial emulation used electronic health records from the University of Pennsylvania Health System from January 2019 to September 2024. Adult men with type 2 diabetes, identified by diagnostic codes, were included. Men with a prior ED diagnosis or end-stage renal disease were excluded.

After stabilized inverse probability of treatment weighting, the analysis included 4,910 patients who initiated a GLP-1 drug and 5,524 who initiated a DPP-4 inhibitor. Mean age was 63, body mass index was 32.8, 55% were white, and 23% were Black. Before weighting, GLP-1 drug users tended to be younger, have a higher prevalence of obesity, and a higher estimated glomerular filtration rate.

Analyses stratified by specific GLP-1 agent suggested a higher ED risk among men prescribed dulaglutide (HR 1.44, 95% CI 1.20-1.73). Estimates for other agents -- semaglutide, tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) -- were modest or imprecise due to small sample sizes.

Chen and co-authors also used U.S. electronic health record data from the TriNetX database to validate their findings. In this analysis, men on GLP-1 drugs had a 13% increased ED risk compared with DPP-4 inhibitor users over nearly 3 years (HR 1.13, 95% CI 1.10-1.17, P<0.001).

The researchers acknowledged a few limitations, including a lack of data on changes in body weight and glycemic control after starting treatment, as well as pre-baseline medication history and diabetes duration. Also, ED was identified using diagnosis codes, which may not capture milder cases and could introduce misclassification.

Disclosures